COMMUNIQUÉS West-GlobeNewswire

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

23/01/2024 - 13:00

The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE [...]

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

23/01/2024 - 13:00

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and [...]

First Wave BioPharma to Present at the DealFlow MicroCap Conference

23/01/2024 - 13:00

BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

23/01/2024 - 13:00

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]

Grow Up Conference & Expo Announces Top 50 Cannabis Leaders in Canada Ahead of CannaVision '24 Executive Summit

23/01/2024 - 13:00

Leading cannabis event company celebrates national leaders and launches an exclusive gathering for decision-makers in the global arena Toronto, ON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Grow Up Conference & Expo (“Grow [...]

A Cut Above: RIFF Cannabis Brand Expands Its Diamond Collection With New THCA ‘Liquid Diamond’ Vapes

23/01/2024 - 13:00

New RIFF Cannabis Collection Includes Diamond-Infused Multi-Packs of Pre-Rolls and Blunts TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading [...]

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

23/01/2024 - 12:50

BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s [...]

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

23/01/2024 - 12:30

Collaboration to accelerate research to determine role of GBA gene CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner [...]

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

23/01/2024 - 12:24

Company Announcement Net sales of DARZALEX ® in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S ( [...]

CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

23/01/2024 - 11:00

First-of-its-kind, antibody-based, bivalent and bispecific MAGE-A4 T-cell engager ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) [...]

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

23/01/2024 - 10:20

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost [...]

HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq

23/01/2024 - 10:20

HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq 1er tour institutionnel pour HEPHAISTOS, en bonne voie pour amener son produit phare ONCO- [...]

German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN

23/01/2024 - 09:30

Avextra, the German pharmaceutical company focused on Cannabis-Based Medicines (CBM) and the German Pain Association (DGS), the leading physicians’ society dedicated to chronic pain therapy, jointly announces their [...]

Ex dividend NOK 0.75 today

23/01/2024 - 08:00

The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.

Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion

23/01/2024 - 08:00

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 23 JANUARY 2024 at 9.00 EET Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion [...]

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

23/01/2024 - 08:00

Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech The rapidly growing $130 billion coffee industry is at risk as [...]

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

23/01/2024 - 07:30

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy and complements 30-year heritage [...]

Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique

23/01/2024 - 07:30

Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique Cette [...]

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure

23/01/2024 - 07:00

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 23 January 2024, 07:00 am CET DSMB i rates DSR 2.0 as safe following review of data from non-randomized cohort Data from non-randomized cohort confirms dramatic [...]